The ICER Impact.

New York Medicaid pursued discounts, many of which were in line with ICER reports, which have saved the state over $300 million

Read More

Engaged with over 300 patient groups and patient reps

In a landmark international program, HTA agencies around the world can now access ICER’s customizable COVID-19 Cost-Effectiveness Model

Read More


Policy Papers.

Easy access to our ongoing policy papers

Unsupported Price Increases

Out of 10 identified drugs that had substantial 2019 price increases on top of already high current spending, seven were not supported by new clinical evidence; the net price increases on these seven drugs alone cost Americans an additional $1.2 billion in annual drug spend.

Read More

Strengthening the FDA’s Accelerated Approval Pathway

This paper aims to create a clearer understanding of both the opportunities and challenges inherent in the FDA’s accelerated approval pathway (AAP), and to present an analysis of the potential risks and benefits of a range of reform options that policymakers may consider in efforts to strengthen the AAP moving forward.

Read More

Cornerstones of ‘Fair’ Drug Coverage

Informed by expert input from patient groups, clinician specialty societies, payers, and life science companies, this white paper provides recommendations for appropriate design and implementation of policies that determine patient access to prescription drugs.

Read More



Group of Patients

Learn more about how the patient perspective influences ICER’s work, and learn how you can be involved.

ICER podcast logo

Listen to our podcast, “A Prescription for Fair Pricing“. Subscribe now on Apple, Google, or Spotify.

Cost-Effectiveness, the evLYG,

the QALY, and Fair Drug Pricing.

Learn More.